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Antenatal administration of corticosteroids is widely used
for preventing a RDS, even though some recent studies have
failed to show a significant lower rate of RDS in treated pre-
term infants· (1, 2 ) . Research of other drugs without the se-
vere contraindications and the unknown long-term effects of
the corticosteroids is the aim of some Perinatal Centers.
Ambroxol has been shown to reduce significantly the incidence
of RDS compared to placebo and not to produce important ad-
verse effects either in mother or infants. Animal experiments
at rabbits and at the G ttinger miniatur-pig have demonstrated
a positive influence of intraamnially applicated lecithin on
the lecithin concentration at the alveolar surface ( 3 , 4 ) .
Clinical observations revealed a quantitative and' qualitative
reduction in the incidence of RDS after intraamnial applica-
tion of lecithin. Intralipid® 10% is a common used drug con-
taining. 100 g/1 sojaoil, 12 g/1 lecithin, 25 g/1 glycerin ad
1000 ml aqua ad iniectabilia.
Pregnant women admitted to the clinic with premature labour
activity took part in the study at the 29th to the 36th week
of gestation after the following procedure: by the first
amniocentesis the lecithin concentration and L/S-ratio were
determined. All patients with a lecithin level <5 mg/100 ml
were randomized in two groups. The first group (n=19) received
^60 ml Intralipid® intraamnially only at day 1, the other
group got 1000 mg Ambroxol/500 ml glucose within 2 hours for
5 days. At day 7 a repunction was performed and lecithin de-
termined. When there was a lower lecithin concentration than
5 mg/100 ml, the above mentioned procedure was repeated. Be-
sides the Apgar indices there were no significant differences
in the characteristics of the patients and the liveborn,
whereas the Apgar score revealed better indices in the Intra-
lipid® group.
The data of the study are demonstrated in figure 3. By these

































Fig. 1: Incidence of RDS after application of Ambroxol
and Xntralipid® (random-study)
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This positive effect of Intralipid® can be demonstrated more
pronounced by including former data of our Intralipid® appli

































Fig. 2: Incidence of RDS after application of Ambroxol
an Intralipid® (non random-study)
(Ref. demanded)
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